This NDC is on FDA's drug shortage list (posted Mar 13, 2023)
Reported reason: Other
Product Information
METHOTREXATE 250 MG/10 ML VIAL is a generic product labeled by Teva Parenteral Medicines, Inc., priced at $0.7020 per ML under NDC 00703367501. Its NADAC has been published 478 times since Nov 28, 2013.
FDA first approved this application on Jan 11, 2010. Its Orange Book therapeutic-equivalence code is AP.
Strength
25 mg/mL
Manufacturer
Teva Parenteral Medicines, Inc.NDC
00703367501
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRA-ARTERIAL; INTRAMUSCULAR; INTRATHECAL; INTRAVENOUS
Effective Date
8/19/2026
Active Ingredients
METHOTREXATE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA040843FDA Approved
1/11/2010
TE Code
AP
On Market Since
8/1/2012
Pharmacological Classes
Price Statistics
The NADAC for METHOTREXATE 250 MG/10 ML VIAL has been published 478 times since Nov 28, 2013, and over the history we have for it it has declined 52.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7020 per ML |
|---|---|
| All-time high | $1.4874 (Dec 11, 2013) |
| All-time low | $0.6670 (Sep 21, 2016) |
| 52-week high | $0.8206 |
| 52-week low | $0.7020 |
| Median price | $0.7984 |
| Average price | $0.7853 |
| Largest weekly change | -45.7% (Dec 18, 2013) |
| Weeks tracked | 478 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of METHOTREXATE 250 MG/10 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 250 MG/10 ML VIAL, manufactured by Teva Parenteral Medicines, Inc., is $0.7020 per ML (NDC 00703367501), effective Aug 19, 2026.
How has the price of METHOTREXATE 250 MG/10 ML VIAL changed over time?
Over the history we have for it, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has declined 52.8%. It has been tracked across 478 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for METHOTREXATE 250 MG/10 ML VIAL?
Since Nov 28, 2013, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has ranged from a low of $0.6670 (Sep 21, 2016) to a high of $1.4874 (Dec 11, 2013), with a median of $0.7984 per ML.
Are there cheaper alternatives to METHOTREXATE 250 MG/10 ML VIAL?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHOTREXATE 1 GRAM/40 ML VIAL, is $0.6450 per ML — about 8% below METHOTREXATE 250 MG/10 ML VIAL.
Who manufactures METHOTREXATE 250 MG/10 ML VIAL?
METHOTREXATE 250 MG/10 ML VIAL (NDC 00703367501) is labeled by Teva Parenteral Medicines, Inc., and CMS classifies it as a generic product.
Is METHOTREXATE 250 MG/10 ML VIAL in shortage?
Yes — NDC 00703367501 is currently listed in FDA's drug shortage database (posted Mar 13, 2023). Reported reason: Other.